ABT - Abbott Laboratories

NYSE - NYSE Delayed price. Currency in USD
100.68
+0.04 (+0.04%)
At close: 4:04PM EDT

100.68 0.00 (0.00%)
After hours: 4:34PM EDT

Stock chart is not supported by your current browser
Previous close100.64
Open101.08
Bid100.63 x 900
Ask101.50 x 1200
Day's range100.21 - 101.55
52-week range61.61 - 102.89
Volume3,543,345
Avg. volume6,085,103
Market cap178.257B
Beta (5Y monthly)0.96
PE ratio (TTM)58.16
EPS (TTM)1.73
Earnings date14 Oct 2020 - 19 Oct 2020
Forward dividend & yield1.44 (1.43%)
Ex-dividend date14 Jul 2020
1y target est105.76
  • 3 Safe Stocks to Hold Through the Next Market Crash
    Motley Fool

    3 Safe Stocks to Hold Through the Next Market Crash

    Abbott Laboratories (NYSE: ABT) makes for a terrific investment for many reasons. For long-term investors, it starts with the Illinois-based company's rich history of dividend growth. Abbott is well on its way to becoming a Dividend King in a couple of years.The dividend currently yields about 1.4% annually, a bit short of the S&P 500 average of 2%.

  • 3 Rock-Solid Healthcare Stocks to Buy in a Market Crash
    Motley Fool

    3 Rock-Solid Healthcare Stocks to Buy in a Market Crash

    During a market crash, it can be common for investors to worry that the stocks they're buying at a dirt-cheap price might not rebound -- that they might experience extended declines and never recover. In most cases, if we invest in companies with profit and revenue growth, it's likely their shares will bounce back. One of the biggest reasons to like Illumina (NASDAQ: ILMN): It's the leader in the genome sequencing market.

  • If You Had Invested $1,000 in Abbott Labs During the Last Recession, This Is How Much You Would Have Today
    Motley Fool

    If You Had Invested $1,000 in Abbott Labs During the Last Recession, This Is How Much You Would Have Today

    Abbott Laboratories (NYSE: ABT) is a blue-chip stock that has been at the forefront of coronavirus testing since the early days of the pandemic. Abbott Labs is shipping millions of these tests to communities, medical providers, and laboratories around the world. In the midst of a global recession, it's normal to think long and hard before investing your hard-earned money.

  • Here's the Least Risky Solid-Growth Coronavirus Stock to Buy Right Now
    Motley Fool

    Here's the Least Risky Solid-Growth Coronavirus Stock to Buy Right Now

    It's hard to keep track of all of the companies developing drug candidates, experimental vaccines, and diagnostics tests focused on fighting COVID-19. Not all of the stocks of the publicly traded companies with COVID-19 programs are great picks for investors, though. If you're looking for the least risky solid-growth coronavirus stock to buy, I think there's one that stands above all the rest: Abbott Laboratories (NYSE: ABT).

  • The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline
    Zacks

    The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline

    The Zacks Analyst Blog Highlights: Bank of America, Abbott Laboratories, Chevron, Danaher and GlaxoSmithKline

  • Covid-19 Testing Is Broken and There's No Plan to Fix It
    Bloomberg

    Covid-19 Testing Is Broken and There's No Plan to Fix It

    (Bloomberg Opinion) -- Many of the recent stories are familiar, but still distressing and perplexing.There was the gentleman in Tucson who waited 27 days to get results from a Covid-19 test, only to discover he didn’t have the virus and the two weeks he spent in quarantine had been pointless. There was the nonprofit nursing home chain in the Phoenix area that waited five days for test results, only to learn that several staff members and residents had the coronavirus; the asymptomatic staffers had roamed freely until the results arrived. And there have been many tales of Arizona residents waiting a week, on average, to get test results — and sometimes much longer — even though their state has been a coronavirus hotspot for more than a month. Texas, Florida, California and many other newly resurgent corona-states have similar stories.Test results, to be useful, should arrive in less than two days. If they take longer, opportunities to isolate infected people and trace their contacts with others wither, undermining broader containment efforts. So why can’t the wealthiest and most innovative country in the world have more rapid-fire testing during a pandemic?Several other wealthy countries already set good examples around testing that the U.S. might have emulated, measures including national testing strategies and aggressive contact tracing. The U.S. also had a lag between its first coronavirus outbreaks in the spring and the current surge, which gave private and public stakeholders in the testing community a chance to catch up. Yet even though testing has ramped up massively — to about 780,000 tests a day, from 145,000 per day in early April — some experts say that to combat the coronavirus effectively the country should be conducting at least 5 million tests a day. Federal health authorities recently said the U.S. has already reached its daily testing capacity, but by fall should have the ability to conduct about 1.3 million to 1.7 million tests a day. That would be an improvement, but clearly not enough — especially if a second coronavirus wave washes across America come October or November.Even now, the spread of the virus has outpaced testing increases. (In Arizona, in-state testing volume jumped 50% while the growth in new Covid-19 cases exceeded 100%.) More testing isn’t a solution anyhow if results aren’t prompt. And the sheer number of cases in the U.S. adds to the problem. During the spring, coronavirus cases peaked at about 36,000 a day. Last Thursday, more than 75,000 infections were reported — a new record. That same day, a bipartisan group of health care experts, scientists, former senior public officials and investors released a report warning of further economic and social devastation if Covid-19 is left unchecked.“Testing is the only way out of our present disaster, and it will remain the case until a vaccine or effective therapeutics are widely available,” noted the report, which was sponsored by the Rockefeller Foundation. The authors call for $75 billion in immediate public spending to buttress the testing effort, which would be “the single best investment America could make in averting an even more tragic and pending disaster.”Even if you don’t believe the coronavirus has brought on an apocalypse, it still makes sense to fix and fortify national testing to protect public health before other disasters arrive. A civilized, equitable and well-functioning country shouldn’t be satisfied with the current testing regime. Rather, it should set to work to establish effective public-private partnerships, embrace the role of the federal and state governments as problem solvers, and hold the private sector to higher standards.While the Trump administration and the federal government have drawn ample criticism for leadership failures around testing, the private sector has also proved unequal to the epic challenges a pandemic presents.Federal agencies such as the Centers for Disease Control and Prevention, state labs and hospitals all provide testing services, but commercial labs dominate the market. The clinical testing business, which generates annual revenue of about $80 billion, has a number of big players, including ARUP Laboratories, BioReference Laboratories, Mayo Clinic Laboratories, and Sonic Healthcare Ltd. But two aggressive competitors, Quest Diagnostics Inc. and Laboratory Corporation of America Holdings, dominate the field.Quest earned $858 million on revenue of $7.7 billion in 2019. The company says its operations “touch the lives” of 30% of the U.S. adult population and it boasts of relationships with about half of all physicians and hospitals in the country. LabCorp earned $824 million on revenue of $11.5 billion last year. It says it interacts with 3 million patients weekly, controls proprietary data derived from 35 billion lab test results (which includes about 50% of the U.S. population), and has contributed to the development of all 50 of the country’s top-selling drugs.Both companies were assembled through decades of mergers and acquisitions, diagnostic ingenuity and an unrelenting focus on expanding their market share. Quest and Labcorp are preferred or exclusive providers for many of the largest private health insurance companies in the U.S., and they process a large portion of tests covered by Medicare and Medicaid.Quest, in its securities filings, describes the testing market as “fragmented and highly competitive.” But Quest and LabCorp’s sales suggest they jointly control about a quarter of the business. Smaller competitors have complained over the years that Quest and Labcorp’s tight relationships with insurers and the federal government make it hard for them to break into health care networks to offer alternatives. Some consumers have alleged that the companies charge exorbitant prices for tests administered to uninsured patients, and both companies have drawn scrutiny for possibly overbilling Medicare and Medicaid (charges that they’ve denied).In the spring, questions about how readily insurers would cover charges from all companies for Covid-19 tests, along with many patients’ reluctance to visit doctors’ offices, brutalized the testing industry’s bottom line. Quest and LabCorp seem to have weathered this better than most; the stocks of both companies are trading around their 52-week highs. Yet even they haven’t been able to meet the testing demands imposed by Covid-19.As the virus rampaged in June and July, both companies, having rapidly upped their testing game, still lagged. A three-to-five-day turnaround time for test results they announced at the end of June gave way to a four-to-five-day delay by the first week of July. After announcing the second delay, Quest said it didn’t expect to get any faster until the coronavirus stopped spreading nationally. Don’t expect that to happen anytime soon. In an interview with the Financial Times on Tuesday, a senior Quest executive said “it will be impossible” for his company “to increase coronavirus testing capacity to cope with demand during the autumn flu season.”That leaves patients, hospitals and society in a bind. Consider Arizona, which has the highest Covid-19 positivity rate of any state. The virus has spread there so quickly and deeply that a public health official in the state’s most populous county has said contact tracing may have become worthless. Sonora Quest Laboratories — a partnership between Quest and the Banner Health hospital chain — handles 80% of Covid-19 tests in Arizona, making it the largest testing network in the state. And it can take 11 days for Sonora Quest to deliver test results.Arizona Governor Doug Ducey, a Republican caught flat-footed by the outbreak, recently channeled $1 million in state funds to Sonora Quest to help buy equipment to process tests more quickly. He’s also started pushing a new testing partnership with Arizona State University, and he’s working with the federal government to set up free testing sites. Perhaps he will have better luck than Phoenix Mayor Kate Gallego, a Democrat, who said she requested federal testing sites in April and was rebuffed by the White House.But Ducey comes late to his testing push, having been reluctant to impose other public health measures such as stay-at-home orders, masks and lockdowns. And regardless of his new incentives, it’s not clear how quickly Sonora Quest can ramp up testing and improve turnaround times.Another governor decided to circumvent the major labs altogether. New York’s Andrew Cuomo, a Democrat, has advised his state’s residents to patronize local labs rather than Quest or LabCorp to get timely test results. About 70% of New York’s tests are now processed by 200 local labs that return results in one to three days, the state said.Smaller labs around the country have excess capacity they’re unable to deploy because they haven’t been able to break into the insurance networks dominated by the big guys. And labs of all sizes struggle to operate at full capacity because a balkanized supply chain forces them to compete against one another for frequently scarce resources.Those resources include reagents (the chemicals labs use to detect the presence of a virus), swabs for collecting patient samples, personal protective equipment, tubes and other media used to transport samples, and proprietary test kits that work with diagnostic machines from companies such as Hologic Inc., Thermo Fisher Scientific Inc. and Abbott Laboratories. Those kits are a special challenge because they’re not interchangeable: Labs that use machines made by Hologic, for example, can’t use kits designed for machines made by Thermo Fisher. A dearth of testing kits was a problem in the spring. Now there’s a dearth of testing machines. All of this has become a tar pit for labs and their employees working around the clock.To top it off, the testing industry has technology and data challenges. As the New York Times recently detailed in a bit of startling reporting, some test results are still transmitted via fax machines and traditional mail, 80% of Covid-19 test results lack demographic information, and 50% have no associated addresses. Privacy requirements explain much of the problem, but it nonetheless hobbles testing during a pandemic.Will companies sort this out on their own? No, because they’re competing against one another. Can states help? No, they’re competing against one another, too. That leaves the federal government as the logical referee. It’s Washington that can define and coordinate a national testing program, provide financial incentives to companies to speed things up, help steer resources so as to rationalize supply chains, and revivify a dilapidated public health infrastructure undermined by years of staffing and budget cuts.However, the possibility of federal action collides with longstanding suspicion, and often outright hostility, in the U.S. toward centralized public health guidance and services. Countering that sentiment, and driving a national testing strategy, will require creative and purposeful leadership from Washington — and from the White House in particular.When Covid-19 first escalated in the spring, President Donald Trump briefly came to recognize there was battle to be fought. “I view it as a, in a sense, a wartime president,” he said in March. “It’s a medical war. We have to win this war. It’s very important.”But one month after setting up a coronavirus task force in the White House and putting his son-in-law, Jared Kushner, in charge of expanding testing, Trump effectively shifted primary responsibility for the battle to the states. It was as if, during World War II, Franklin D. Roosevelt had told governors to devise their own military strategies and produce their own tanks, ships and planes.During the brief period the White House took the reins, some progress was made. More testing sites were opened and significant supply chain problems were tackled. An effort to offer drive-through testing services in commercial parking lots got underway. But Trump’s promise in the spring that “anybody that wants a test can get a test” wasn’t true then and it’s still not true today — largely because the president failed to forge a national consensus around testing in partnership with governors and public and private laboratories.More recently, Trump has repeatedly denounced testing. And the White House has been trying to cut billions of dollars for testing and other public health initiatives that Republicans in Congress want baked into the next round of bailout funding. At a press briefing on Tuesday, Trump declined to say whether he personally supported further funding for testing. In the midst of a national crisis, that animus toward testing is reckless and dangerous.Whoever is elected president in November may be enjoying his victory just as Covid-19 unleashes a brutal winter surge. Whether that’s Trump or Joe Biden, he will need to put the weight of the federal government behind initiatives to bolster public health services generally and break the testing logjam specifically.An obvious first step would be for the White House to help speed up the creation and distribution of simple point-of-care tests that can be used in doctors’ offices, private residences, nursing homes, schools — anywhere they’re needed outside of laboratory settings, especially in underserved, low-income communities. These tests can produce results in an hour or less, but also have significant accuracy problems. There’s already ample research underway to improve POC tests, and the federal government has approved a small number for emergency use, including devices from Abbott, Quidel Corp. and Becton, Dickinson and Company. But there’s much work to be done there.The U.S. has been playing catch-up on coronavirus testing almost from the start, ever since the faulty Covid-19 test the CDC sent to labs in early February turned out to be disastrously ineffective. Since then the government, which previously handled the development and distribution of diagnostic tests, has granted a series of emergency approvals for private companies to produce new tests. In contrast, Germany and South Korea have kept looser leashes on test development, bolstering their ability to test more broadly and effectively. The U.S. government would do well to continue loosening some of its testing regulations.On the other hand, the government could use its regulatory powers to suppress any anti-competitive practices that some of the bigger testing companies may be engaging in. A more muscular interpretation of the Defense Production Act would also enable the White House to resolve myriad supply problems, whether by ensuring the availability and compatibility of testing equipment or by smoothing access to such basics as swabs and reagents.The CDC, which Trump has undermined, could help institute a more effective testing regime by working with its traditional network of state public health agencies and private companies — if its budget was fortified and its regulatory and legal powers were enhanced. The CDC currently offers guidelines that states can take or leave. An empowered CDC should be authorized to devise enforceable rules that help rationalize how the testing industry operates.Analysts, experts and medical professionals from ideologically diverse institutions — including the American Enterprise Institute, Duke University, Harvard University, Johns Hopkins University and the Rockefeller Foundation — have recently issued detailed reports calling for bolder steps to streamline and reinvent the U.S. testing system. All of them advocate a broader role for the federal government, ranging from coordinating information and supplies and supporting POC innovations to providing financial incentives, establishing private-public mega-labs, and establishing task forces to help carry out these initiatives.The Harvard study goes so far as to call for the creation of a federal “Pandemic Testing Board” with “strong but narrow powers that has the job of securing the testing supply and the infrastructure necessary for deployment of testing.” The authors liken this to the War Production Board that the U.S. empowered for three years during World War II to supervise the production of weapons and military supplies.That makes sense to me. After all, we won World War II and we’re now at war with Covid-19. Even Trump knows that.This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Timothy L. O'Brien is a senior columnist for Bloomberg Opinion.For more articles like this, please visit us at bloomberg.com/opinionSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.

  • Top Stock Reports for Bank of America, Abbott & Chevron
    Zacks

    Top Stock Reports for Bank of America, Abbott & Chevron

    Top Stock Reports for Bank of America, Abbott & Chevron

  • Have $2,000? Consider Buying These 2 Top Coronavirus Stocks
    Motley Fool

    Have $2,000? Consider Buying These 2 Top Coronavirus Stocks

    After all, buying shares of great companies -- and holding these shares for long periods -- remains one of the best ways to accumulate wealth. In case you do, and if you still have $2,000 lying around, here are two stocks that could be great long-term picks: Abbott Laboratories (NYSE: ABT) and Pfizer (NYSE: PFE). Abbott Laboratories has developed five COVID-19 diagnostic tests, one of which is the ID Now COVID-19 antibody test.

  • Abbott Laboratories Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
    Simply Wall St.

    Abbott Laboratories Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

    A week ago, Abbott Laboratories (NYSE:ABT) came out with a strong set of second-quarter numbers that could potentially...

  • I Ran A Stock Scan For Earnings Growth And Abbott Laboratories (NYSE:ABT) Passed With Ease
    Simply Wall St.

    I Ran A Stock Scan For Earnings Growth And Abbott Laboratories (NYSE:ABT) Passed With Ease

    For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

  • Abbott Laboratories Beats on Q2 Estimates, But Stock Slides
    Motley Fool

    Abbott Laboratories Beats on Q2 Estimates, But Stock Slides

    Although it's popular as a coronavirus stock these days, Abbot Laboratories (NYSE: ABT) nevertheless is struggling with other areas of its business. On average, they believed Abbott would take in $6.81 billion in sales and post an adjusted net profit of $0.42 per share. Two of the company's four business lines -- its largest, medical devices, and established pharmaceuticals -- saw notably lower sales during the quarter, falling a respective 21% and nearly 9%.

  • Coronavirus update: Walmart, Target, CVS lead corporate push for face masks amid US case spike
    Yahoo Finance

    Coronavirus update: Walmart, Target, CVS lead corporate push for face masks amid US case spike

    The U.S. had another near-record spike in coronavirus cases, prompting a growing number of major corporations to enforce masking in their establishments.

  • Abbott Labs' Earnings Sink in Q2 but Still Trounce Wall Street Estimates
    Motley Fool

    Abbott Labs' Earnings Sink in Q2 but Still Trounce Wall Street Estimates

    Abbott Labs (NYSE: ABT) suspended its full-year 2020 guidance in April because of uncertainty about the COVID-19 pandemic. Investors found out whether or not Abbott continued to win on Thursday with the healthcare giant announcing its second-quarter results before the market opened. Here are the highlights from Abbott's Q2 update.

  • Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid
    Zacks

    Abbott (ABT) Q2 Earnings Top, Coronavirus Test Sales Solid

    Abbott (ABT) Q2 earnings reflect healthy growth within its Diabetes Care business and encouraging coronavirus test sales.

  • Abbott (ABT) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Abbott (ABT) Q2 Earnings and Revenues Beat Estimates

    Abbott (ABT) delivered earnings and revenue surprises of 32.56% and 7.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

  • 5 Earnings Charts for the Coronavirus Recovery
    Zacks

    5 Earnings Charts for the Coronavirus Recovery

    Drug makers, restaurants, industrials and transports will tell you what is really going on in the US economy.

  • Why Earnings Season Could Be Great for Abbott (ABT)
    Zacks

    Why Earnings Season Could Be Great for Abbott (ABT)

    Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Abbott Laboratories and Edwards Lifesciences Settle Patent Fight
    Motley Fool

    Abbott Laboratories and Edwards Lifesciences Settle Patent Fight

    The two companies' agreement puts to rest an escalating dispute over heart valve repair products.

  • The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing
    Zacks

    The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

    The Zacks Analyst Blog Highlights: Oracle, Abbott Laboratories, Chevron, Sanofi and Boeing

  • Coronavirus Tests Rollout to Drive Abbott (ABT) Q2 Earnings?
    Zacks

    Coronavirus Tests Rollout to Drive Abbott (ABT) Q2 Earnings?

    Abbott (ABT) is entangled in issues like procedural delays for its non-coronavirus products, which may have impacted its Q2 earnings.

  • Earnings season kicks off with big banks, Netflix: What to know in the week ahead
    Yahoo Finance

    Earnings season kicks off with big banks, Netflix: What to know in the week ahead

    Market participants are bracing for the start of what will likely be the weakest corporate earnings season since the global financial crisis, as the coronavirus pandemic and measures to contain it hit business activity especially hard in the second quarter.

  • Have $5,000? 3 Coronavirus Stocks You Can Buy in July Without Losing Any Sleep
    Motley Fool

    Have $5,000? 3 Coronavirus Stocks You Can Buy in July Without Losing Any Sleep

    These healthcare leaders give you a relatively low-risk way to invest in the fight against COVID-19.

  • Top Analyst Reports for Oracle, Abbott & Chevron
    Zacks

    Top Analyst Reports for Oracle, Abbott & Chevron

    Top Analyst Reports for Oracle, Abbott & Chevron

  • Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for

    Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

    Is (ABT) Outperforming Other Medical Stocks This Year?